About Intradigm Corporation
Intradigm Corporation is a company based in Palo Alto (United States) founded in 2000 was acquired by Silence Therapeutics in December 2009.. Intradigm Corporation has raised $37.4 million across 2 funding rounds from investors including Roche, Novartis and Silence Therapeutics. Intradigm Corporation operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter Palo Alto, United States
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Intradigm Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$37.4 M (USD)
in 2 rounds
-
Latest Funding Round
$21.4 M (USD), Series B
Jan 07, 2009
-
Investors
Roche
& 10 more
-
Employee Count
Employee Count
-
Acquired by
Silence Therapeutics
(Dec 16, 2009)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Intradigm Corporation
Intradigm Corporation has successfully raised a total of $37.4M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $21.4 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $21.4M
-
First Round
First Round
(01 May 2006)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2009 | Amount | Series B - Intradigm Corporation | Valuation | Astellas Venture Management | |
| May, 2006 | Amount | Series A - Intradigm Corporation | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Intradigm Corporation
Intradigm Corporation has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Novartis and Silence Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A venture capital firm focused on life science innovations.
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Intradigm Corporation
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Intradigm Corporation
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Intradigm Corporation Comparisons
Competitors of Intradigm Corporation
Intradigm Corporation operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Intradigm Corporation
Frequently Asked Questions about Intradigm Corporation
When was Intradigm Corporation founded?
Intradigm Corporation was founded in 2000 and raised its 1st funding round 6 years after it was founded.
Where is Intradigm Corporation located?
Intradigm Corporation is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Is Intradigm Corporation a funded company?
Intradigm Corporation is a funded company, having raised a total of $37.4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $16M, raised on May 01, 2006.
What does Intradigm Corporation do?
Intradigm Corporation was founded in 2000 and is based in Palo Alto, United States. Focus is placed on the biotechnology sector, where RNA interference therapeutics are developed for serious diseases, starting with oncology. Operations involve the use of proprietary Nanoplex delivery technology, which allows targeted administration to specific tissues via systemic drug delivery methods.
Who are the top competitors of Intradigm Corporation?
Intradigm Corporation's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Intradigm Corporation's investors?
Intradigm Corporation has 11 investors. Key investors include Roche, Novartis, Silence Therapeutics, Genentech, and Frazier Healthcare Partners.